Information Provided By:
Fly News Breaks for September 9, 2015
CELG
Sep 9, 2015 | 08:47 EDT
Bernstein estimates that Celgene's Ozanimod drug, a treatment for MS, ulcerative colitis and Crohn's disease, will generate revenue of $2.5B in 2022, up from $500M in 2019. The firm thinks the drug's revenue could be 50% above those levels if it succeeds in Phase III tests and its profile is consistent with the firm's expectations. Bernstein keeps an Outperform rating on Celgene.
News For CELG From the Last 2 Days
There are no results for your query CELG